Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Operating Expenses (2017 - 2026)

Lexaria Bioscience's Operating Expenses history spans 10 years, with the latest figure at $1.5 million for Q1 2026.

  • Quarterly results put Operating Expenses at $1.5 million for Q1 2026, down 49.68% from a year ago — trailing twelve months through Feb 2026 was $9.8 million (down 0.79% YoY), and the annual figure for FY2025 was $12.6 million, up 102.56%.
  • Operating Expenses for Q1 2026 was $1.5 million at Lexaria Bioscience, down from $1.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $3.9 million in Q2 2025 to a low of $813005.0 in Q1 2024.
  • The 5-year median for Operating Expenses is $1.8 million (2022), against an average of $2.0 million.
  • The sharpest move saw Operating Expenses surged 259.78% in 2025, then plummeted 49.68% in 2026.
  • Year by year, Operating Expenses stood at $1.8 million in 2022, then fell by 27.67% to $1.3 million in 2023, then surged by 123.39% to $2.9 million in 2024, then tumbled by 45.21% to $1.6 million in 2025, then fell by 6.46% to $1.5 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $1.5 million, $1.6 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.